{"answer":{"query":"rexulti","resolved_as":"name","packages":6,"applications":["NDA205422"],"identity":{"application_numbers":["NDA205422"],"marketing_categories":["NDA"],"labelers":[{"text":"OTSUKA AMERICA PHARMACEUTICALS, INC.","untrusted":true}],"dosage_forms":[{"text":"TABLET","untrusted":true}],"marketing_start":{"earliest":"2015-07-10","latest":"2015-07-10","packages_with_a_start_date":6}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":6,"negotiated_price_ends":null,"rows":[{"ndc":"59148003513","name":{"text":"REXULTI 0.25 mg tablet","untrusted":true},"class":"B","nadac_per_unit":49.49046,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59148003613","name":{"text":"REXULTI 0.5 mg tablet","untrusted":true},"class":"B","nadac_per_unit":49.48264,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59148003713","name":{"text":"REXULTI 1.0 mg tablet","untrusted":true},"class":"B","nadac_per_unit":49.56135,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59148003813","name":{"text":"REXULTI 2.0 mg tablet","untrusted":true},"class":"B","nadac_per_unit":49.52468,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59148003913","name":{"text":"REXULTI 3.0 mg tablet","untrusted":true},"class":"B","nadac_per_unit":49.4906,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"59148004013","name":{"text":"REXULTI 4.0 mg tablet","untrusted":true},"class":"B","nadac_per_unit":49.5475,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":null},"generic_entry":[{"application":"NDA205422","date":"2033-04-12","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"10307419*PED","productNo":"004"},"latest_patent_expiry":"2033-04-12","latest_exclusivity_expiry":"2028-05-09","dated_barriers":88,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":5,"exclusivities_listed":5,"fact_id":"bae5d7cb52bc3595a20fd055"}],"label_history":{"events_total":11,"non_cmc_events":11,"counts_by_class":{"LABELING":6,"EFFICACY":5},"cmc_events":0,"recent_non_cmc_events":[{"application":"NDA205422","submission_no":17,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-04-30","documents":[{"type":"Letter","date":"2026-05-04","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/205422Orig1s017ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-05-05","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/205422s017lbl.pdf","untrusted":true}}],"fact_id":"649bd842a5d7674bb902db44"},{"application":"NDA205422","submission_no":14,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-05-09","documents":[{"type":"Letter","date":"2025-05-15","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/205422Orig1s014ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-05-09","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205422s014lbl.pdf","untrusted":true}}],"fact_id":"01328395445ef4c17d3007da"},{"application":"NDA205422","submission_no":13,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-12-11","documents":[{"type":"Letter","date":"2024-12-13","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/205422Orig1s013ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-12-13","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205422Orig1s013lbl.pdf","untrusted":true}}],"fact_id":"aef86599fda6ff67fe582829"},{"application":"NDA205422","submission_no":11,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2024-05-07","documents":[{"type":"Letter","date":"2024-05-08","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/205422Orig1s011ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-05-08","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205422s011lblcorrection.pdf","untrusted":true}}],"fact_id":"78c46116005fe859d0f373e0"},{"application":"NDA205422","submission_no":9,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2023-05-10","documents":[{"type":"Label","date":"2023-05-11","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205422s009lbl.pdf","untrusted":true}},{"type":"Letter","date":"2023-05-11","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/205422Orig1s009ltr.pdf","untrusted":true}}],"fact_id":"2bd0ae2015bea0e2536619ba"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":6,"te_code_counts":{"AB":6},"marketing_status_counts":{"Prescription":6},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA205422","product_no":"006","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"REXULTI","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"4MG","untrusted":true}},{"application":"NDA205422","product_no":"004","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"REXULTI","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"2MG","untrusted":true}},{"application":"NDA205422","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"REXULTI","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"0.5MG","untrusted":true}},{"application":"NDA205422","product_no":"005","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"REXULTI","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"3MG","untrusted":true}},{"application":"NDA205422","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"REXULTI","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"0.25MG","untrusted":true}},{"application":"NDA205422","product_no":"003","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"REXULTI","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"1MG","untrusted":true}}]},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"BREXPIPRAZOLE","untrusted":true},"recruiting_interventional_count":5,"not_yet_recruiting_count":2,"by_phase":{"PHASE3":2,"PHASE1":1,"PHASE4":1,"PHASE2":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT05325645","title":{"text":"Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Otsuka Pharmaceutical Co., Ltd.","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-09-16","start_date":"2022-07-21","link":{"text":"https://clinicaltrials.gov/study/NCT05325645","untrusted":true}},{"nct_id":"NCT04569448","title":{"text":"Brexpiprazole Treatment for Bipolar I Depression","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Douglas Mental Health University Institute","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-08-27","start_date":"2021-05-10","link":{"text":"https://clinicaltrials.gov/study/NCT04569448","untrusted":true}},{"nct_id":"NCT06674694","title":{"text":"The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Sichuan Kelun Pharmaceutical Co.,Ltd.","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-06-29","start_date":"2024-04-10","link":{"text":"https://clinicaltrials.gov/study/NCT06674694","untrusted":true}},{"nct_id":"NCT05017311","title":{"text":"Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Nova Scotia Health Authority","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-06-11","start_date":"2023-01-20","link":{"text":"https://clinicaltrials.gov/study/NCT05017311","untrusted":true}},{"nct_id":"NCT04066192","title":{"text":"Brexpiprazole in Alcohol Use Disorder","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"University of Colorado, Denver","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-05-01","start_date":"2020-10-30","link":{"text":"https://clinicaltrials.gov/study/NCT04066192","untrusted":true}}],"fact_id":"9cc238ba1de2895dad77e99f"}]},"spending":{"reported_under":{"generic":{"text":"Brexpiprazole","untrusted":true},"brand":{"text":"Rexulti","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":358159996.5,"claims":282200,"beneficiaries":41111,"average_spending_per_claim_usd":1269.1707884,"fact_id":"e6e8f860af2c4feea2249f05"},{"year":2021,"gross_spending_usd":403387369.19,"claims":298638,"beneficiaries":43616,"average_spending_per_claim_usd":1350.7570008,"fact_id":"96b928b4c62f3facb7fc7f88"},{"year":2022,"gross_spending_usd":490498962.75,"claims":327951,"beneficiaries":49620,"average_spending_per_claim_usd":1495.647102,"fact_id":"bd5143d77a75ef00f660e698"},{"year":2023,"gross_spending_usd":630013840.43,"claims":407145,"beneficiaries":66421,"average_spending_per_claim_usd":1547.3942709,"fact_id":"65eea45226e526c220b771db"},{"year":2024,"gross_spending_usd":861392149.79,"claims":598492,"beneficiaries":94695,"average_spending_per_claim_usd":1439.2709506,"fact_id":"e06662376521c196e730967f"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"medicaid_state_utilization":{"year":2025,"states_with_data":6,"all_states_medicaid_reimbursed_usd":891672.79,"all_states_medicaid_paid_prescriptions":558,"top_states":[{"state":"NH","medicaid_paid_prescriptions":136,"medicaid_reimbursed_usd":202575.02,"total_reimbursed_usd":202575.02,"packages":1,"covers":"fee_for_service_only","fact_id":"944aea27b0f197d0f0033969"},{"state":"MN","medicaid_paid_prescriptions":108,"medicaid_reimbursed_usd":162914.47,"total_reimbursed_usd":162914.47,"packages":1,"covers":"fee_for_service_only","fact_id":"2231d8d7d8ad5574ad06ab6f"},{"state":"AL","medicaid_paid_prescriptions":115,"medicaid_reimbursed_usd":161019.23,"total_reimbursed_usd":162647.2,"packages":1,"covers":"all_record_types","fact_id":"1e09e0d37e5c69b4e91dec56"},{"state":"NV","medicaid_paid_prescriptions":67,"medicaid_reimbursed_usd":138388.7,"total_reimbursed_usd":139806.4,"packages":1,"covers":"fee_for_service_only","fact_id":"c3635e421068d23ee996799d"},{"state":"VT","medicaid_paid_prescriptions":62,"medicaid_reimbursed_usd":124119.83,"total_reimbursed_usd":124119.83,"packages":1,"covers":"all_record_types","fact_id":"20f8ccf29551500a88825fe3"},{"state":"RI","medicaid_paid_prescriptions":70,"medicaid_reimbursed_usd":102655.54,"total_reimbursed_usd":102655.54,"packages":1,"covers":"all_record_types","fact_id":"36864ccb7ae0c8f712ca07f7"}],"unlabelled_state_code_xx":null,"built_from_facts":6,"facts_fee_for_service_only":3,"older_year_facts_not_used":268,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"98fc73298b56037557b60c34","field":"ndc.listing","entity":"ndc:59148003513"},{"fact_id":"a85d86ef30c73cc2c33dde88","field":"ndc.listing","entity":"ndc:59148003613"},{"fact_id":"3c2e1797cd426e97ab558d78","field":"ndc.listing","entity":"ndc:59148003713"},{"fact_id":"bae5d7cb52bc3595a20fd055","field":"drug.generic_entry_earliest","entity":"application:NDA205422"},{"fact_id":"30b70b6081a0f7221ece1b23","field":"drug.patent","entity":"application:NDA205422"},{"fact_id":"b064cdd9ced4e4053436f69a","field":"drug.exclusivity","entity":"application:NDA205422"},{"fact_id":"649bd842a5d7674bb902db44","field":"drug.label_event","entity":"application:NDA205422"},{"fact_id":"01328395445ef4c17d3007da","field":"drug.label_event","entity":"application:NDA205422"},{"fact_id":"aef86599fda6ff67fe582829","field":"drug.label_event","entity":"application:NDA205422"},{"fact_id":"78c46116005fe859d0f373e0","field":"drug.label_event","entity":"application:NDA205422"},{"fact_id":"2bd0ae2015bea0e2536619ba","field":"drug.label_event","entity":"application:NDA205422"},{"fact_id":"b7b3db0b220f1d7bfc69ecba","field":"drug.te_code","entity":"application:NDA205422"},{"fact_id":"662a88f7bc55015d3cb80266","field":"drug.marketing_status","entity":"application:NDA205422"},{"fact_id":"b19f0510e5f29ff41e81252f","field":"drug.te_code","entity":"application:NDA205422"},{"fact_id":"86b2487d6e3a0b568f1b5782","field":"drug.marketing_status","entity":"application:NDA205422"},{"fact_id":"7b05bac8e6f7fd5d9af826a0","field":"drug.te_code","entity":"application:NDA205422"},{"fact_id":"826e1d0420a77ea61e808cd8","field":"drug.marketing_status","entity":"application:NDA205422"},{"fact_id":"66dae23249dac2cd63b995fa","field":"drug.te_code","entity":"application:NDA205422"},{"fact_id":"4fc74245a20b45491a8d11e6","field":"drug.marketing_status","entity":"application:NDA205422"},{"fact_id":"562164e489c64820962552dc","field":"drug.te_code","entity":"application:NDA205422"},{"fact_id":"151afa5f995df5e417f8972f","field":"drug.marketing_status","entity":"application:NDA205422"},{"fact_id":"52f1bac4f1c10ec636ea5f6a","field":"drug.te_code","entity":"application:NDA205422"},{"fact_id":"8d7b7cf0b1072eb3a1562619","field":"drug.marketing_status","entity":"application:NDA205422"},{"fact_id":"9cc238ba1de2895dad77e99f","field":"drug.trial_access","entity":"drug:brexpiprazole"},{"fact_id":"e6e8f860af2c4feea2249f05","field":"drug.partd_spending","entity":"drug:brexpiprazole|rexulti"},{"fact_id":"96b928b4c62f3facb7fc7f88","field":"drug.partd_spending","entity":"drug:brexpiprazole|rexulti"},{"fact_id":"bd5143d77a75ef00f660e698","field":"drug.partd_spending","entity":"drug:brexpiprazole|rexulti"},{"fact_id":"65eea45226e526c220b771db","field":"drug.partd_spending","entity":"drug:brexpiprazole|rexulti"},{"fact_id":"e06662376521c196e730967f","field":"drug.partd_spending","entity":"drug:brexpiprazole|rexulti"},{"fact_id":"944aea27b0f197d0f0033969","field":"ndc.medicaid_state_utilization","entity":"ndc_state:59148003913:NH"},{"fact_id":"2231d8d7d8ad5574ad06ab6f","field":"ndc.medicaid_state_utilization","entity":"ndc_state:59148003513:MN"},{"fact_id":"1e09e0d37e5c69b4e91dec56","field":"ndc.medicaid_state_utilization","entity":"ndc_state:59148003513:AL"},{"fact_id":"c3635e421068d23ee996799d","field":"ndc.medicaid_state_utilization","entity":"ndc_state:59148003513:NV"},{"fact_id":"20f8ccf29551500a88825fe3","field":"ndc.medicaid_state_utilization","entity":"ndc_state:59148003713:VT"},{"fact_id":"36864ccb7ae0c8f712ca07f7","field":"ndc.medicaid_state_utilization","entity":"ndc_state:59148004013:RI"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}